Atossa Therapeutics Inc (NASDAQ:ATOS)
| 0.6948 Delayed Data As of Mar 24 |  +0.0155 / +2.28%Today’s Change | 0.50 Today|||52-Week Range 1.54 | +31.47% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $85.9M |
Company Description
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Contact Information
Atossa Therapeutics, Inc. 107 Spring Street Seattle Washington 98104 |
Employees
Shareholders
| Other institutional | 8.13% |
| Mutual fund holders | 6.05% |
| Individual stakeholders | 0.00% |
Top Executives
| Steven C. Quay | Chairman, President & Chief Executive Officer |
| Kyle Guse | CFO, Secretary & Chief Accounting Officer |
| Bernadine Heather Fraser | VP-Clinical, Regulatory & CMC Division |
| Richard Graydon | Chief Medical Officer |
| Delly Behen | Vice President-Administration & Human Resource |
